A plaintiff who alleged harm from the use of a generic drug has had her claim preempted as a result of recent U.S. Supreme Court rulings.

The Fourth Circuit ruled in Drager v. Pliva Tuesday that a generic drugmaker “may not unilaterally change its labeling or change its design or formulation, and cannot be required to exist the market or accept state tort liability.”